Stock Details
LLY is Eli Lilly and Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 314.09$. Average daily volumn in 3 months 2.73M. Market cap 307.24B

Stock symbol : LLY. Exchange : NYSE. Currency : USD
Lastest price : 323.35$. Total volume : 4.21M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Eli Lilly and Company (LLY)
Last Price

Previous Close330.01
Day Range322.42-329.51
Bid323.00 x 900
Ask323.80 x 1.1k
Average Volume2.73M
Market Cap307.24B
52 Week Range224.22-341.70
Trailing P/E51.57
Foward P/E33.16
Dividend (Yield %)1.21%
Ex-Dividend Date2022-08-12

Financial Details

According to Eli Lilly and Company's financial reports the company's revenue in 2021 were 28.32B an increase( +16.67%) over the years 2020 revenue that were of 24.54B. In 2021 the company's total earnings were 5.58B while total earnings in 2020 were 6.19B(-16.67%).

Loading ...


Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramz... a for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.


Market Cap:
Total Assets:
Total Cash:

News about "Eli Lilly and Company"


Eli Lilly and Company (NYSE:LLY) Delivered A Better ROE Than Its Industry

Source from : Nasdaq - 1 days ago

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. To keep the lesson grounded in practicality, we'll use ROE to better understand ...See details»


A Closer Look At Eli Lilly and Company's (NYSE:LLY) Impressive ROE

Source from : YAHOO!Finance - 3 days ago

While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...See details»


Eli Lilly and Company (NYSE:LLY) Shares Sold by Harel Insurance Investments & Financial Services Ltd.

Source from : Defense World - 1 days ago

Harel Insurance Investments & Financial Services Ltd. trimmed its position in Eli Lilly and Company (NYSE:LLY โ€“ Get Rating) by 94.3% during the 2nd quarter, according to the company in its most recent ...See details»


Here Are 25 Billion Reasons to Invest in Eli Lilly

Source from : Nasdaq - 3 days ago

Eli Lilly and its shareholders are sitting pretty right now. The company has defied the broader market sell-off -- with its stock climbing by 11% since the beginning of the year.See details»


Eli Lilly's Donanemab: Nearing The End Of The Line For Anti-Amyloid Drugs

Source from : Seeking Alpha - 14 hours ago

Anti-amyloid drugs only modestly slow down the progression of Alzheimer's in APOE4 carriers and have no effect on non-carriers. Read what it means for Eli Lilly.See details»


Eli Lilly and Company (NYSE:LLY) Receives Average Recommendation of โ€œModerate Buyโ€ from Analysts

Source from : Defense World - 2 days ago

Eli Lilly and Company (NYSE:LLY โ€“ Get Rating) has received a consensus recommendation of โ€œModerate Buyโ€ from the seventeen research firms that are covering the stock, Marketbeat Ratings reports. Two ...See details»


Eli Lilly sued for age discrimination by U.S. agency EEOC

Source from : Yahoo - 4 days ago

Eli Lilly and Co was sued on Monday by the U.S. Equal Employment Opportunity Commission, which accused the drugmaker of illegally refusing to hire older workers for sales representative jobs because ...See details»


Eli Lilly: Valuation Feels Impossibly High - Don't Board This Hype Train

Source from : Seeking Alpha - 3 days ago

Eli Lilly's share price performance over the past 5 years is +290% while the rest of the US Big Pharma sector averages a gain of ~30%. Click here to read more.See details»

Eli Lilly and Company (NYSE:LLY) is favoured by institutional owners who hold 84% of the company

Source from : Yahoo - 7 days ago

If you want to know who really controls Eli Lilly and Company (NYSE:LLY), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are ...See details»

Eli Lilly and Co. is on the hunt for a large expansion in South San Francisco

Source from : The Business Journals - 4 days ago

Drug giant Eli Lilly and Co. is on the hunt for 300,000 square feet of additional space in South San Francisco. Multiple sources with knowledge of the company's real estate strategy confirmed the ...See details»


POWER 100 No. 3: David Ricks lays foundation for life-sciences sector here with Eli Lilly

Source from : The Business Journals - 2 days ago

A year ago, pharmaceutical giant Eli Lilly and Co. did not have a presence in the Charlotte region. Now, the companyโ€™s efforts here, led by David Ricks as chairman and CEO, are expected to play a ...See details»


Here's why Biogen's promising Alzheimer's drug data is also good news for Eli Lilly

Source from : CNBC - 3 days ago

We don't own Eli Lilly exclusively for its potential Alzheimer's treatment. However, we still find Biogen's topline data to be very encouraging for Lilly.See details»

Analyst loves Eli Lilly for its potential blockbuster obesity drug โ€” and we do, too

Source from : CNBC - 9 days ago

The company is completing additional studies focused on its weight-loss potential, but the early results have been so promising that Eli Lilly has approached the FDA about getting the drug ...See details»


Is Eli Lilly and Company's (NYSE:LLY) 66% ROE Better Than Average?

Source from : currently.att - 11 days ago

While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...See details»